| 1.8439 0.009 (0.47%) | 10-12 11:38 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.86 | 1-year : | 3.31 |
| Resists | First : | 2.45 | Second : | 2.83 |
| Pivot price | 2.21  |
|||
| Supports | First : | 1.83 | Second : | 1.52 |
| MAs | MA(5) : | 1.92 |
MA(20) : | 2.26 |
| MA(100) : | 1.95 |
MA(250) : | 2.19 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 2.5  |
D(3) : | 3.5 |
| RSI | RSI(14): 37.8 |
|||
| 52-week | High : | 3.21 | Low : | 1.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BMRA ] has closed above bottom band by 18.1%. Bollinger Bands are 126.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.87 - 1.89 | 1.89 - 1.9 |
| Low: | 1.8 - 1.82 | 1.82 - 1.83 |
| Close: | 1.81 - 1.84 | 1.84 - 1.86 |
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Thu, 08 Oct 2026
BIOMERICA INC SEC Filing (Oct 8, 2026) - Stock Titan
Mon, 28 Sep 2026
CEO and directors bought into Biomerica (BMRA)'s $2.23 million share sale. - Stock Titan
Thu, 17 Sep 2026
Biomerica Inc. (BMRA) Holds Near $2.36 as Traders Eye Tight Range - Extension Target - siam.in
Fri, 04 Sep 2026
Biomerica Inc. (BMRA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Wed, 02 Sep 2026
Biomerica director Gary M. Huff acquires $50,000 in BMRA stock - Investing.com
Mon, 31 Aug 2026
BIOMERICA INC FY 2026: Revenue $4.45M, EPS $(1.30) — 10-K Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 17.9 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 28 (K) |
| Shares Short P.Month | 58 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | -84.8 % |
| Operating Margin | -175.2 % |
| Return on Assets (ttm) | -52.4 % |
| Return on Equity (ttm) | -112.1 % |
| Qtrly Rev. Growth | 16.7 % |
| Gross Profit (p.s.) | 0.07 |
| Sales Per Share | 0.96 |
| EBITDA (p.s.) | -1.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.44 |
| PEG Ratio | 0 |
| Price to Book value | 2.28 |
| Price to Sales | 1.93 |
| Price to Cash Flow | -2.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|